ArticleAnnals of the rheumatic diseases2015
Plasmablasts as a biomarker for IgG4-related disease, independent of serum IgG4 concentrations.
Article in Annals of the rheumatic diseases, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 197 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
197 citing papers in PubMed, 5 syntheses or guidelines pooled it, 489 citations in OpenAlex.
- European Guideline on IgG4-related digestive disease - UEG and SGF evidence-based recommendations.United European gastroenterology journal · 2020Guideline
- Immunoglobulin G4-related hypertrophic pachymeningitis: A case-oriented review.Neurology(R) neuroimmunology & neuroinflammation · 2019Pooled it
- Pulmonary vascular involvement of IgG4-related disease: Case series with a PRISMA-compliant systemic review.Medicine · 2019Pooled it
- Diagnostic Value of Serum IgG4 for IgG4-Related Disease: A PRISMA-compliant Systematic Review and Meta-analysis.Medicine · 2016Pooled it
- IgG4-related disease: a systematic review of this unrecognized disease in pediatrics.Pediatric rheumatology online journal · 2016Pooled it
- B cell and aquaporin-4 antibody relationships with neuromyelitis optica spectrum disorder activity.Annals of clinical and translational neurology · 2024Trial
- Long-term efficacy and safety of rituximab in IgG4-related disease: Data from a French nationwide study of thirty-three patients.PloS one · 2017Trial
- Spinal nerve root IgG4-related inflammatory pseudotumor mimicking a malignant spinal tumor: a case report.European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society · 2026Article
- Proptosis Revealing a Neurological Form of IgG4-Related Disease: A Case Report and Literature Review.Cureus · 2026Article
- Proof-of-concept study: longitudinal immune biomarker signatures in treatment-naïve IgG4-related disease.Scientific reports · 2026Article
- Efficacy and Safety of Obexelimab to Treat IgG4-Related Disease: Protocol for a Global, Randomized, Placebo-Controlled Trial.Rheumatology and therapy · 2026Article
- Management of IgG4-Related Disease.Current rheumatology reports · 2026Review
- Single-cell RNA sequencing and high-dimensional flow cytometry reveal distinct peripheral immune landscapes of type 1 autoimmune pancreatitis and pancreatic ductal adenocarcinoma.Clinical and translational medicine · 2026Article
- Immunological Biomarkers to Assess Activity and Treatment Response in IgG4-Related Disease.Medicina (Kaunas, Lithuania) · 2026Article
- Effects of anti-CD19 CAR-T cells in a murine model of IgG4-related disease.Arthritis research & therapy · 2026Article
- Plasmablasts as Translational Biomarkers in Autoimmune Diseases: From Cellular Dynamics to Clinical Decision-Making.Current issues in molecular biology · 2026Review
- B cell receptor signaling in autoimmune rheumatic diseases: regulatory mechanisms and therapeutic targeting.Frontiers in immunology · 2026Review
- Correlations between IgG4-related disease, autoimmune pancreatitis, and allergic diseases.Frontiers in immunology · 2026Review
- IgG4-related sclerosing cholangitis: navigating diagnostic dilemmas and the challenge of relapse.Frontiers in medicine · 2026Review
- Smoking-associated IgG4-positive cell infiltration in rheumatoid arthritis lung: an exploratory cross-sectional study.Frontiers in immunology · 2026Article
137 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
Abstract
objectivesWe examined the utility of circulating total and IgG4+ plasmablasts as biomarkers of diagnosis and disease activity in IgG4-related disease (IgG4-RD). MATERIALS
methodsWe evaluated patients with active, untreated, biopsy-proven IgG4-RD affecting various organs. Flow cytometry was used to measure total plasmablast and IgG4+ plasmablast counts by gating peripheral blood for CD19lowCD38+CD20-CD27+ cells and CD19lowCD38+CD20-CD27+IgG4+ cells. Serum IgG4 concentrations were measured by nephelometry. We compared 37 IgG4-RD patients to 35 controls, including healthy individuals (n=14) and patients with other inflammatory diseases before treatment (n=21).
resultsThe IgG4-RD patients' mean age was 59, and 68% were male. Fourteen patients (38%) had three or more organs involved. The IgG4-RD patients had substantially elevated total plasmablast counts (median 4698/mL, range 610-79524/mL) compared to both untreated disease controls (median 592/mL, range 19-4294/mL; p < 0.001) and healthy controls (median 94/mL, range 1-653/mL; p < 0.001). Thirteen IgG4-RD patients (36%) had normal serum IgG4 concentrations (mean 60 mg/dL, range 5-123 mg/dL, normal <135 mg/dL). However, the median plasmablast count was not significantly lower in that subset with normal serum IgG4 concentrations (3784/mL) compared to those with elevated serum IgG4 (5155/mL) (p = 0.242). Among the 12 rituximab (RTX)-treated patients, the median plasmablast level during disease flare was 6356/mL (range 1123-41589/mL), declining to 1419/mL (range 386/mL-4150/mL) during remission (p < 0.01).
conclusionsCirculating plasmablasts are elevated in active IgG4-RD, even in patients with normal serum IgG4 concentrations. Plasmablast counts are a potentially useful biomarker for diagnosis, assessing response to treatment, and determining the appropriate time for re-treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.